Modality
ADC
MOA
CD3xCD20
Target
PI3Kα
Pathway
Sphingolipid
Atopic DermPsA
Development Pipeline
Preclinical
Jan 2019
→ Jul 2028
PreclinicalCurrent
NCT06076309
872 pts·Atopic Derm
2020-03→2026-10·Not yet recruiting
NCT03390008
2,044 pts·Atopic Derm
2019-01→2028-07·Recruiting
2,916 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-016mo awayInterim· Atopic Derm
2028-07-182.3y awayInterim· Atopic Derm
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Recruit…
Preclinical
Not yet…
Catalysts
Interim
2026-10-01 · 6mo away
Atopic Derm
Interim
2028-07-18 · 2.3y away
Atopic Derm
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06076309 | Preclinical | Atopic Derm | Not yet recr... | 872 | MRD |
| NCT03390008 | Preclinical | Atopic Derm | Recruiting | 2044 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |